From NVIDIA: 2025-04-22 09:00:00

Over a billion people worldwide are affected by neurological disorders, sparking BrainStorm Therapeutics to harness AI and organoids in drug discovery. Their goal is to reduce the 93% clinical trial failure rate for brain disease drugs and develop treatments faster and more economically.

BrainStorm Therapeutics’ AI models, powered by NVIDIA GPUs, are revolutionizing drug discovery by developing gene maps and testing thousands of drug molecules on human brain cells daily. They aim to accelerate timelines, reduce costs, and increase the likelihood of successful therapies for patients.

By using patient-derived organoids, BrainStorm is making strides in drug discovery for Parkinson’s disease. Their AI models analyze genetic variants and cellular pathways to discover treatments that could slow, halt, or reverse the disease’s progression.

BrainStorm’s innovative approach led to the discovery that Donepezil, an Alzheimer’s drug, could benefit patients with Rett syndrome. They plan to develop multimodal AI models to understand diseases better and find more effective drug candidates, with a focus on precision medicine and rare disease research.

The company is collaborating with the CURE5 Foundation to conduct a comprehensive drug screen for CDKL5 Deficiency Disorder, showcasing how AI-powered organoid technology and NVIDIA resources are transforming rare disease research with accelerated innovation at a reduced cost.



Read more at NVIDIA: AI Startup Speeds Disease Research With Lab in the Loop